Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

MAD2 Expression in Ovarian Carcinoma: Different Expression Patterns and Levels among Various Types of Ovarian Carcinoma and Its Prognostic Significance in High-Grade Serous Carcinoma.

Park PE, Jeong JY, Kim SZ, Park JY.

Korean J Pathol. 2013 Oct;47(5):418-25. doi: 10.4132/KoreanJPathol.2013.47.5.418. Epub 2013 Oct 25.

2.

Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.

J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. Erratum in: J Pathol. 2014 Feb;232(3):e1.

3.

Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer.

McGrogan B, Phelan S, Fitzpatrick P, Maguire A, Prencipe M, Brennan D, Doyle E, O'Grady A, Kay E, Furlong F, McCann A.

Hum Pathol. 2014 Jul;45(7):1509-19. doi: 10.1016/j.humpath.2014.03.004. Epub 2014 Mar 27.

PMID:
24792619
4.

Expression of the mitotic-arrest deficiency 2 is associated with chemotherapy resistance in ovarian serous adenocarcinoma.

Nakano Y, Sumi T, Teramae M, Morishita M, Fukuda T, Terada H, Yoshida H, Matsumoto Y, Yasui T, Ishiko O.

Oncol Rep. 2012 Oct;28(4):1200-4. doi: 10.3892/or.2012.1907. Epub 2012 Jul 12.

PMID:
22797604
5.

[Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].

Shen XX, Yu L, Bi R, Yang WT.

Zhonghua Bing Li Xue Za Zhi. 2011 Aug;40(8):511-6. Chinese.

PMID:
22169637
6.

Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.

Taube ET, Denkert C, Sehouli J, Kunze CA, Dietel M, Braicu I, Letsch A, Darb-Esfahani S.

Gynecol Oncol. 2016 Mar;140(3):494-502. doi: 10.1016/j.ygyno.2015.12.018. Epub 2015 Dec 22.

PMID:
26721227
7.

Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells.

Wang X, Jin DY, Ng RW, Feng H, Wong YC, Cheung AL, Tsao SW.

Cancer Res. 2002 Mar 15;62(6):1662-8. Erratum in: Cancer Res. 2012 Apr 1;72(7):1905. Cancer Res. 2005 Mar 1;65(5):2045.

8.

High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer.

Choi JW, Kim Y, Lee JH, Kim YS.

Virchows Arch. 2013 Nov;463(5):681-7. doi: 10.1007/s00428-013-1473-6. Epub 2013 Aug 31.

PMID:
23995871
9.

Clinicopathologic significance of mitotic arrest defective protein 2 overexpression in hepatocellular carcinoma.

Zhang SH, Xu AM, Chen XF, Li DH, Sun MP, Wang YJ.

Hum Pathol. 2008 Dec;39(12):1827-34. doi: 10.1016/j.humpath.2008.06.003. Epub 2008 Aug 20.

PMID:
18715617
10.

[Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].

Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.

Zhonghua Fu Chan Ke Za Zhi. 2007 Apr;42(4):227-32. Chinese.

PMID:
17631760
11.

The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.

Cho D, Park H, Park SH, Kim K, Chung M, Moon W, Kang M, Jang K.

J Ovarian Res. 2015 Feb 15;8:2. doi: 10.1186/s13048-015-0129-3.

12.

MAD2 expression in oral squamous cell carcinoma and its relationship to tumor grade and proliferation.

Rizzardi C, Torelli L, Schneider M, Giudici F, Zandona L, Biasotto M, Di Lenarda R, Melato M.

Anticancer Res. 2014 Dec;34(12):7021-7.

PMID:
25503128
13.

DEF6 expression in ovarian carcinoma correlates with poor patient survival.

Liew PL, Fang CY, Lee YC, Lee YC, Chen CL, Chu JS.

Diagn Pathol. 2016 Aug 3;11(1):68. doi: 10.1186/s13000-016-0518-y.

14.

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Jöhrens K.

Oncotarget. 2016 Jan 12;7(2):1486-99. doi: 10.18632/oncotarget.6429.

15.

Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.

Unger U, Denkert C, Braicu I, Sehouli J, Dietel M, Loibl S, Darb-Esfahani S.

Virchows Arch. 2017 Feb;470(2):143-151. doi: 10.1007/s00428-016-2050-6. Epub 2016 Dec 2.

PMID:
27913862
16.

Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.

Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ.

Oncotarget. 2016 Mar 15;7(11):12267-85. doi: 10.18632/oncotarget.7860.

17.

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.

Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM.

Clin Cancer Res. 2004 Oct 1;10(19):6432-6.

18.
19.

Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells.

Bargiela-Iparraguirre J, Prado-Marchal L, Pajuelo-Lozano N, Jiménez B, Perona R, Sánchez-Pérez I.

Cell Cycle. 2014;13(22):3590-601. doi: 10.4161/15384101.2014.962952.

20.

[Expression and clinicopathologic significance of CD44v6/CD24 in ovarian serous carcinomas].

Wang A, Lu L, Wang Y, Sun Y, Zhang Y, Guo C, Gu Y, Liu A.

Zhonghua Bing Li Xue Za Zhi. 2014 Jan;43(1):20-4. Chinese.

PMID:
24713244

Supplemental Content

Support Center